Ann: Botanix Initiates BTX 1702 Rosacea Study, page-17

I'm not sure what the estimate of market sales might be however it was reported from the AGM that they are doing a trial to depopulate the nose of superbugs.

- currently patients going in for surgery are treated with bactroban to reduce the risk of infection. Bactroban does suffer from bacteria developing resistance to it

- there is talk of community treatment to reduce the prevalence of super bugs within the community. This would need to be done with a product that doesn't suffer from bacteria building resistance to it .... hello BTX1801

- obviously there is a market for a product in the exact area that is being trialled, however they are going way as a first step as it's treating surface bacteria, so the likelihood of a positive outcome is very high given their pre-clinical work showing CBD's bactericidal action.

- after a successful 1801 trial, they will then look to trial in other applications. The nasal treatment alone would be a significant market, the many other applications will mean the antimicrobial market potential will dwarf their other products

It was mentioned at one point after the release of their pre-clinical results for 1801 that there was potential for it to go straight into ph2, given the known safety profile of CBD and the FDA's willingness to expedite new treatments for super bugs.